+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Lymphopenia in Wegener’s Granulomatosis

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Significant lymphopenia is a prominent feature in systemic erythematous lupus, but has not been described in Wegener’s granulomatosis (WG). We suggest from a retrospective analysis that lymphopenia may also be an index of WG disease activity. Methods: Medical charts form 19 patients diagnosed with systemic active WG between 1990 and 2000 were reviewed retrospectively. All patients had crescentic glomerulonephritis and alveolar hemorrhage. Clinical and biological markers were reviewed at three different time points: diagnosis, time of relapse, and during remission. Results: Average lymphocyte count was significantly lower at diagnosis and relapse than during remission times (p < 0.008 and p < 0.000002, respectively). During disease activity either at diagnosis and during relapses, ANCA titers were highly positive (≧50 IU/ml) in 27.5% of patients (8/29). The corresponding lymphocyte counts were below normal (1,500/min<sup>3</sup>) in 28 of 29 patients (96.5%). In patients with either negative or weakly positive ANCA, mean lymphocyte count was 728.5, 744.2 and 2,551/ml at diagnosis, during relapse and remission times, respectively. There was a clear negative correlation between the lymphocyte count and disease activity. Conclusion: Lymphopenia appears to be a good marker of WG activity. This index might be useful in all patients including those with negative ANCA.

          Related collections

          Author and article information

          S. Karger AG
          October 2002
          02 September 2002
          : 92
          : 2
          : 466-471
          Departments of aNephrology and bInternal Medicine, Pitié Salpétrière Hospital, Paris, France
          63303 Nephron 2002;92:466–471
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 3, Tables: 2, References: 21, Pages: 6
          Self URI (application/pdf):
          Short Communication

          Cardiovascular Medicine, Nephrology

          Lymphopenia, Disease activity, Wegener granulomatosis


          Comment on this article